Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

医学 特应性皮炎 随机对照试验 皮肤病科 外科
作者
Eric L. Simpson,Seth Forman,Jonathan I. Silverberg,Matthew Zirwas,Emanual Maverakis,George Han,Emma Guttman‐Yassky,Daniel Marnell,Robert Bissonnette,Jill Waibel,Fabio P. Nunes,Amy M. DeLozier,Robinette Angle,Margaret Gamalo,Katrin Holzwarth,Orin M. Goldblum,Jinglin Zhong,Jonathan Janes,Kim Papp
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:85 (1): 62-70 被引量:108
标识
DOI:10.1016/j.jaad.2021.02.028
摘要

Background Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Methods Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index at week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD score of 0 (clear)/1(almost clear) with ≥2-point improvement. Results At week 16, the proportion of patients achieving Eczema Area and Severity Index was 8%, 13%, and 30% (P < .001, 2 mg vs placebo) and those with a validated Investigator Global Assessment for AD score of 0/1 were 5%, 13%, and 24% (P < .001, 2 mg vs placebo) for placebo, baricitinib 1 mg, and baricitinib 2 mg, respectively. Safety findings were similar to those of other baricitinib AD studies. Limitations Short-term clinical trial results may not be generalizable to real-world settings. Conclusion Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks. Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index at week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD score of 0 (clear)/1(almost clear) with ≥2-point improvement. At week 16, the proportion of patients achieving Eczema Area and Severity Index was 8%, 13%, and 30% (P < .001, 2 mg vs placebo) and those with a validated Investigator Global Assessment for AD score of 0/1 were 5%, 13%, and 24% (P < .001, 2 mg vs placebo) for placebo, baricitinib 1 mg, and baricitinib 2 mg, respectively. Safety findings were similar to those of other baricitinib AD studies. Short-term clinical trial results may not be generalizable to real-world settings. Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Ava应助dildil采纳,获得10
1秒前
3秒前
3秒前
124dc发布了新的文献求助10
3秒前
Owen应助2418478262采纳,获得10
3秒前
4秒前
量子星尘发布了新的文献求助10
5秒前
Neinei发布了新的文献求助10
6秒前
领导范儿应助00小费0采纳,获得10
6秒前
7秒前
Sml发布了新的文献求助10
9秒前
plum发布了新的文献求助10
9秒前
晨曦完成签到 ,获得积分10
10秒前
Jaho完成签到,获得积分10
11秒前
悦耳凡波关注了科研通微信公众号
12秒前
15秒前
Ali完成签到,获得积分10
17秒前
18秒前
19秒前
20秒前
SYLH应助自由的鼠标采纳,获得10
20秒前
anzhi发布了新的文献求助10
21秒前
21秒前
隐形曼青应助WK采纳,获得10
22秒前
23秒前
23秒前
23秒前
大模型应助Steven采纳,获得10
24秒前
fmx完成签到,获得积分10
25秒前
汉堡包应助杨天哲采纳,获得10
25秒前
2418478262发布了新的文献求助10
26秒前
26秒前
27秒前
老阎应助葡萄爱吃荔枝采纳,获得30
27秒前
Neinei完成签到,获得积分10
28秒前
slayer完成签到 ,获得积分10
29秒前
31秒前
31秒前
小蚊子发布了新的文献求助10
31秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3977986
求助须知:如何正确求助?哪些是违规求助? 3522138
关于积分的说明 11211677
捐赠科研通 3259360
什么是DOI,文献DOI怎么找? 1799602
邀请新用户注册赠送积分活动 878476
科研通“疑难数据库(出版商)”最低求助积分说明 806918